GREENFIELD, Ind. / Jul 20, 2023 / Business Wire / Elanco Animal Health Incorporated (NYSE:ELAN) today released its 2022 Environmental, Social and Governance (ESG) Report highlighting enhanced governance, transparency and progress measurements.
Elanco’s commitment to important ESG-related topics is demonstrated across its four interconnected Healthy Purpose™ Pillars: Healthier Animals, Healthier People, Healthier Planet and Healthier Enterprise. Through numerous internal initiatives and external collaborations within each pillar, Elanco is working to positively impact global concerns such as food security and nutrition, human health and well-being, and environmental sustainability.
“Healthy animals are essential for a healthy world. This belief is embedded in our vision – Food and Companionship Enriching Life – and is the anchor to Elanco's approach to ESG-related matters and advancing our sustainability goals," said Jeff Simmons, President and CEO Elanco. "This year's report includes examples of our impact as a global organization. For instance, between 2020 and 2022, we've helped beef and dairy customers avoid an estimated 7.2 million metric tons of CO2e emissions by using Rumensin™ – roughly equivalent to taking 1.6 million1 passenger cars off the road for a year. Additionally, through multiple logistics initiatives, in 2022 we reduced transportation and distribution emissions more than 10% from the prior year.”
Along with this year’s report, the company introduced a collection of supporting issue briefs containing meaningful oversight and procedural disclosures for leading ESG issues and enhanced performance metrics demonstrating Elanco’s ongoing commitment to transparency.
Key highlights from Elanco’s 2022 ESG Report:
Healthier Animals: Helping pets and farm animals live healthy, high-quality lives by continuously expanding our existing portfolio while identifying new and innovative animal care products, practices and services to support animal health and well-being because making life better for animals makes life better.
Healthier People: Improving lives and livelihoods by promoting animal companionship and enabling healthier and more sustainable meat, milk, fish and egg production.
Healthier Planet: Minimizing the company’s environmental footprint while leveraging product and service innovations to help stakeholders advance their sustainability efforts.
Healthier Enterprise: Growing Elanco’s business with integrity and excellence with respect for all stakeholders, fostering an inclusive culture where employees can make a difference – encouraging ownership, growth and well-being.
For details on the company’s ESG disclosures, policies, programs and initiatives, visit elanco.com/en-us/sustainability.
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose– all to advance the health of animals, people, the planet and our enterprise. Learn more at www.elanco.com
1 Estimated equivalency calculated via the U.S. EPA Greenhouse Gas Equivalencies Calculator, Greenhouse Gas Equivalencies Calculator | US EPA
Last Trade: | US$8.44 |
Daily Change: | 0.34 4.20 |
Daily Volume: | 5,109,870 |
Market Cap: | US$4.170B |
February 25, 2025 February 25, 2025 November 15, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load